Corey Davis
Stock Analyst at HC Wainwright & Co.
(2.94)
# 1,315
Out of 5,182 analysts
17
Total ratings
75%
Success rate
25.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corey Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Reiterates: Neutral | $480 → $390 | $76.99 | +406.56% | 5 | May 12, 2020 | |
| SCYX SCYNEXIS | Assumes: Buy | $50 | $0.89 | +5,531.26% | 3 | May 7, 2018 | |
| VTVT vTv Therapeutics | Downgrades: Neutral | $560 → $40 | $41.17 | -2.84% | 2 | Apr 10, 2018 | |
| LPCN Lipocine | Initiates: Buy | $170 | $2.05 | +8,192.68% | 1 | Mar 29, 2018 | |
| VNDA Vanda Pharmaceuticals | Initiates: Buy | $20 | $7.00 | +185.71% | 2 | Jan 19, 2018 | |
| PCRX Pacira BioSciences | Initiates: Buy | $50 | $22.70 | +120.26% | 3 | Jan 19, 2018 | |
| JAZZ Jazz Pharmaceuticals | Initiates: Neutral | $144 | $186.95 | -22.97% | 1 | Aug 25, 2017 |
Nektar Therapeutics
May 12, 2020
Reiterates: Neutral
Price Target: $480 → $390
Current: $76.99
Upside: +406.56%
SCYNEXIS
May 7, 2018
Assumes: Buy
Price Target: $50
Current: $0.89
Upside: +5,531.26%
vTv Therapeutics
Apr 10, 2018
Downgrades: Neutral
Price Target: $560 → $40
Current: $41.17
Upside: -2.84%
Lipocine
Mar 29, 2018
Initiates: Buy
Price Target: $170
Current: $2.05
Upside: +8,192.68%
Vanda Pharmaceuticals
Jan 19, 2018
Initiates: Buy
Price Target: $20
Current: $7.00
Upside: +185.71%
Pacira BioSciences
Jan 19, 2018
Initiates: Buy
Price Target: $50
Current: $22.70
Upside: +120.26%
Jazz Pharmaceuticals
Aug 25, 2017
Initiates: Neutral
Price Target: $144
Current: $186.95
Upside: -22.97%